Millet J, Vaillot M, Theveniaux J, Brown N L
Recherche et Developpement, Laboratoires Fournier, Daix, France.
Thromb Res. 1996 Feb 15;81(4):497-502. doi: 10.1016/0049-3848(96)00023-0.
To investigate the effects of new drugs on the prevention of venous thrombosis, the Wessler stasis model is extensively employed usually in the rabbit. In this model, a hypercoagulable state is achieved by the administration of either heterologous serum (often human serum) or an activated coagulation factor followed by total stasis of the vein in which the thrombus is to be formed. Although classically the stasis model is performed in rabbits, it is possible to induce experimental venous thrombosis in a number of animal species, including rats. However, the use of homologous serum as the activating or thrombogenic agent has been previously described only in the dog and in the rabbit. The purpose of the present study was to compare the activities of heterologous and homologous serum as hypercoagulating agents in a rat stasis model of venous thrombosis using Wessler's technique. Heparin was employed as a reference antithrombotic compound in order to compare the two thrombogenic challenges.
为研究新药对预防静脉血栓形成的作用,通常广泛采用韦氏停滞模型,在兔身上进行实验。在该模型中,通过给予异种血清(通常为人血清)或活化凝血因子,然后使要形成血栓的静脉完全停滞,从而达到高凝状态。尽管传统上停滞模型是在兔身上进行的,但在包括大鼠在内的多种动物物种中诱导实验性静脉血栓形成也是可能的。然而,以前仅在犬和兔中描述过使用同源血清作为激活剂或致血栓形成剂。本研究的目的是使用韦氏技术,比较异种血清和同源血清作为高凝剂在大鼠静脉血栓形成停滞模型中的活性。使用肝素作为参考抗血栓化合物,以比较两种致血栓形成的刺激因素。